Two critically ill COVID-19 infected patients, who had exhausted all available treatment options, were treated with the small-molecule RRx-001 with subsequent improvement. RRx-001, a first-in-class small molecule with anti-inflammatory, vascular normalizing and macrophage-repolarizing properties, has been safely administered 300+ patients in clinical trials. This is the first report of RRx-001 treatment of COVID-19.
CITATION STYLE
Hammond, T. C., Lee, R. C., Oronsky, B., Reid, T. R., Caroen, S., Juarez, T. M., … Kesari, S. (2022). Clinical Course of Two Patients with COVID-19 Respiratory Failure After Administration of the Anticancer Small Molecule, RRx-001. International Medical Case Reports Journal, 15, 735–738. https://doi.org/10.2147/IMCRJ.S389690
Mendeley helps you to discover research relevant for your work.